Expression of peroxisome proliferator-activated receptor subtypes in human atherosclerosis

被引:0
|
作者
Sueyoshi, S [1 ]
Yamada, T
Niihasi, M
Kusumi, Y
Oinuma, T
Esumi, M
Tsuru, K
Imai, S
Nemoto, N
Sakura, I
Mitsumata, M
机构
[1] Nihon Univ, Dept Pathol, Sch Med, Tokyo, Japan
[2] Kyorin Pharmaceut Co Ltd, Res Ctr, Nogi, Tochigi, Japan
来源
ATHEROSCLEROSIS VI | 2001年 / 947卷
关键词
peroxisome proliferator-activated receptor (PPAR); atherosclerosis; mRNA; atheromatous plaque; fatty streak; intimal thickening;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To clarify the involvement of peroxisome proliferator-activated receptors (PPARs) in atherosclerotic plaque formation, we investigated the expression patterns of mRNA and protein of PPARalpha and PPARgamma in human aorta. Atheromatous plaque, fatty streak, and diffuse intimal thickening (DIT) were separated macroscopically, and each sample was divided into halves. Half of them were used for analysis of mRNA expression with reverse transcription-polymerase chain reaction and the others were used for histologic analysis. Both PPARalpha and PPARgamma mRNA were detected in all atheromatous plaques, all fatty streaks, and in some DIT. However, expressions of PPARalpha and PPARgamma were obviously less frequently found in DIT than in atheromatous plaques, and the intensity of these expressions was stronger in the atheromatous plaques than in the DIT. Compared with PPARalpha, PPARgamma mRNA was expressed more frequently in atheromatous plaques. In atheromatous plaques, PPARgamma mRNA was expressed independently, whereas PPARalpha mRNA was coexpressed with PPARgamma. PPARgamma protein was obviously found in the nuclei of endothelial cells, macrophages, mononuclear cells, and smooth muscle cells in the aortic intima. These results suggest that expressions of PPARalpha and PPARgamma in human aortic wall are involved in atherogenesis from the early stages.
引用
收藏
页码:429 / 432
页数:4
相关论文
共 50 条
  • [31] Absence of peroxisome proliferator-activated receptor-γ abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse
    Tordjman, Karen M.
    Semenkovich, Clay F.
    Coleman, Trey
    Yudovich, Rachel
    Bak, Stella
    Osher, Etty
    Vechoropoulos, Michal
    Stern, Naftali
    HYPERTENSION, 2007, 50 (05) : 945 - 951
  • [32] Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
    Ivanova, Ekaterina A.
    Myasoedova, Veronika A.
    Melnichenko, Alexandra A.
    Orekhov, Alexander N.
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (07) : 1119 - 1124
  • [33] Imbalance of peroxisome proliferator-activated receptor gamma and adiponectin predisposes Kawasaki disease patients to developing atherosclerosis
    Fukunaga, Hideo
    Kishiro, Masahiko
    Akimoto, Katsumi
    Ohtsuka, Yoshikazu
    Nagata, Satoru
    Shimizu, Toshiaki
    PEDIATRICS INTERNATIONAL, 2010, 52 (05) : 795 - 800
  • [34] Atherosclerosis modulates the electrophysiological effects of a peroxisome proliferator-activated receptor-gamma activator on pulmonary veins
    Cheng, Chen-Chuan
    Pan, Nan-Hung
    Chen, Yao-Chang
    Yeh, Hung-I
    Lin, Cheng-I
    Chen, Shih-Ann
    Chen, Yi-Jen
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 145 (03) : 578 - 582
  • [35] Peroxisome proliferator-activated receptors for hypertension
    Usuda, Daisuke
    Kanda, Tsugiyasu
    WORLD JOURNAL OF CARDIOLOGY, 2014, 6 (08): : 744 - 754
  • [36] Peroxisome proliferator-activated receptor α controls cellular cholesterol trafficking in macrophages
    Chinetti-Gbaguidi, G
    Rigamonti, E
    Helin, L
    Mutka, AL
    Lepore, M
    Fruchart, JC
    Clavey, V
    Ikonen, E
    Lestavel, S
    Staels, B
    JOURNAL OF LIPID RESEARCH, 2005, 46 (12) : 2717 - 2725
  • [37] Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future
    Daniel H. van Raalte
    Min Li
    P. Haydn Pritchard
    Kishor M. Wasan
    Pharmaceutical Research, 2004, 21 : 1531 - 1538
  • [38] Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?
    Blaschke, F
    Bruemmer, D
    Law, RE
    CLINICAL CARDIOLOGY, 2004, 27 (07) : 3 - 10
  • [39] Peroxisome proliferator-activated receptor α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease
    Flavell, DM
    Jamshidi, Y
    Hawe, E
    Torra, LP
    Taskinen, MR
    Frick, MH
    Nieminen, MS
    Kesäniemi, YA
    Pasternack, A
    Staels, B
    Miller, G
    Humphries, SE
    Talmud, PJ
    Syvänne, M
    CIRCULATION, 2002, 105 (12) : 1440 - 1445
  • [40] Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor γ
    Zhao, Duo
    Zhu, Zhicheng
    Li, Dan
    Xu, Rihao
    Wang, Tiance
    Liu, Kexiang
    BIOCHEMISTRY, 2015, 54 (45) : 6806 - 6814